Zelicapavir not checked

Enanta Pharmaceuticals, Inc · EDP-938

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
11 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
RSV (2 trials), RSV Infection, Respiratory Syncytial Virus (RSV)
Main trialPhase 2/3
“Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either ≥75 years of age or ≥18 years of age with COPD and/or CHF. Participants will be non-hospitalized adults who have up to 72 hours of respiratory tract infection symptoms and test positive for RSV.”In the company’s words, NCT07908381 on ClinicalTrials.gov
Other names
EDP-938

Other drugs for RSV

All 55 drugs for RSV

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting Jul 2029 A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Phase 2Recruiting Dec 2026 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Phase 2Completed 30 Sep 2019 A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
Phase 2Completed 4 Jan 2022 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Phase 2Terminated 31 May 2023 Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
Phase 2Completed 19 Aug 2024 A Study to Evaluate EDP 938 Regimens in Children With RSV
Phase 2Completed 23 Jun 2025 A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
Phase 1Completed 30 Mar 2021 Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
Phase 1Completed 27 May 2021 Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Phase 1Completed 4 Jul 2021 Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
Phase 1Completed 2 Feb 2025 A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zelicapavir

Following is part of Solo: you see every change to Zelicapavir the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in